University of Hertfordshire

Standard

Circulation of Highly Drug-Resistant Clostridium difficile Ribotypes 027 and 001 in Two Tertiary-Care Hospitals in Mexico. / Adrian Martinez-Melendez, Adrian; Tijerina-Rodrıguez, Laura; Morfin-Otero, Rayo; Camacho-Ortiz, Adrian; Villarreal-Trevino, Licet; Sanchez-Alanıs, Hugo; Rodrıguez-Noriega, Eduardo; Baines, Simon; Flores-Trevino, Samantha; Maldonado-Garza, Hector Jesus ; Garza-Gonzalez, Elvira.

In: Microbial Drug Resistance, Vol. 24, No. 4, 01.05.2018, p. 386-392.

Research output: Contribution to journalArticle

Harvard

Adrian Martinez-Melendez, A, Tijerina-Rodrıguez, L, Morfin-Otero, R, Camacho-Ortiz, A, Villarreal-Trevino, L, Sanchez-Alanıs, H, Rodrıguez-Noriega, E, Baines, S, Flores-Trevino, S, Maldonado-Garza, HJ & Garza-Gonzalez, E 2018, 'Circulation of Highly Drug-Resistant Clostridium difficile Ribotypes 027 and 001 in Two Tertiary-Care Hospitals in Mexico', Microbial Drug Resistance, vol. 24, no. 4, pp. 386-392. https://doi.org/10.1089/mdr.2017.0323

APA

Adrian Martinez-Melendez, A., Tijerina-Rodrıguez, L., Morfin-Otero, R., Camacho-Ortiz, A., Villarreal-Trevino, L., Sanchez-Alanıs, H., ... Garza-Gonzalez, E. (2018). Circulation of Highly Drug-Resistant Clostridium difficile Ribotypes 027 and 001 in Two Tertiary-Care Hospitals in Mexico. Microbial Drug Resistance, 24(4), 386-392. https://doi.org/10.1089/mdr.2017.0323

Vancouver

Adrian Martinez-Melendez A, Tijerina-Rodrıguez L, Morfin-Otero R, Camacho-Ortiz A, Villarreal-Trevino L, Sanchez-Alanıs H et al. Circulation of Highly Drug-Resistant Clostridium difficile Ribotypes 027 and 001 in Two Tertiary-Care Hospitals in Mexico. Microbial Drug Resistance. 2018 May 1;24(4):386-392. https://doi.org/10.1089/mdr.2017.0323

Author

Adrian Martinez-Melendez, Adrian ; Tijerina-Rodrıguez, Laura ; Morfin-Otero, Rayo ; Camacho-Ortiz, Adrian ; Villarreal-Trevino, Licet ; Sanchez-Alanıs, Hugo ; Rodrıguez-Noriega, Eduardo ; Baines, Simon ; Flores-Trevino, Samantha ; Maldonado-Garza, Hector Jesus ; Garza-Gonzalez, Elvira. / Circulation of Highly Drug-Resistant Clostridium difficile Ribotypes 027 and 001 in Two Tertiary-Care Hospitals in Mexico. In: Microbial Drug Resistance. 2018 ; Vol. 24, No. 4. pp. 386-392.

Bibtex

@article{522841ed69234ef7b724148af6108ffd,
title = "Circulation of Highly Drug-Resistant Clostridium difficile Ribotypes 027 and 001 in Two Tertiary-Care Hospitals in Mexico",
abstract = "OBJECTIVE: To assess drug susceptibility and characterize Clostridium difficile ribotypes in isolates from two tertiary-care hospitals in Mexico.METHODS: Isolates were evaluated for genotyping, antimicrobial susceptibility testing and detection of mutations associated with drug resistance. PCR ribotyping was performed using a combination of gel-based and capillary electrophoresis-based approaches.RESULTS: MIC50 and MIC90 were ≥128 mg/L for ciprofloxacin, erythromycin, clindamycin, and rifampicin. There was no reduced susceptibility to metronidazole or tetracycline; however, reduced susceptibility to vancomycin (≥4 mg/L) and fidaxomicin (≥2 mg/L) was detected in 50 (40.3{\%}) and 4 (3.2{\%}) isolates, respectively. Furthermore, the rpoB Arg505Lys mutation was more frequently detected in isolates with high minimum inhibitory concentration (MIC) to rifampicin (≥32 mg/L) (OR = 52.5; 95{\%} CI = 5.17-532.6; p < 0.000). Of the 124 C. difficile isolates recovered, 84 (66.7{\%}) were of ribotype 027, 18 (14.5{\%}) of ribotype 001, and the remainder were other ribotypes (353, 255, 220, 208, 176, 106, 076, 020, 019, 017, 014, 012, 003, and 002).CONCLUSION: Ribotypes 027 and 001 were the most frequent C. difficile isolates recovered in this study, and demonstrated higher MICs. Furthermore, we found four isolates with reduced susceptibility to fidaxomicin, raising a concern since this drug is currently unavailable in Mexican Hospitals.",
keywords = "Clostridium difficile, drug resistance, fidaxomicin, ribotype 001, ribotypes",
author = "{Adrian Martinez-Melendez}, Adrian and Laura Tijerina-Rodrıguez and Rayo Morfin-Otero and Adrian Camacho-Ortiz and Licet Villarreal-Trevino and Hugo Sanchez-Alanıs and Eduardo Rodrıguez-Noriega and Simon Baines and Samantha Flores-Trevino and Maldonado-Garza, {Hector Jesus} and Elvira Garza-Gonzalez",
note = "{\circledC} 2018, Mary Ann Liebert, Inc.",
year = "2018",
month = "5",
day = "1",
doi = "10.1089/mdr.2017.0323",
language = "English",
volume = "24",
pages = "386--392",
journal = "Microbial Drug Resistance",
number = "4",

}

RIS

TY - JOUR

T1 - Circulation of Highly Drug-Resistant Clostridium difficile Ribotypes 027 and 001 in Two Tertiary-Care Hospitals in Mexico

AU - Adrian Martinez-Melendez, Adrian

AU - Tijerina-Rodrıguez, Laura

AU - Morfin-Otero, Rayo

AU - Camacho-Ortiz, Adrian

AU - Villarreal-Trevino, Licet

AU - Sanchez-Alanıs, Hugo

AU - Rodrıguez-Noriega, Eduardo

AU - Baines, Simon

AU - Flores-Trevino, Samantha

AU - Maldonado-Garza, Hector Jesus

AU - Garza-Gonzalez, Elvira

N1 - © 2018, Mary Ann Liebert, Inc.

PY - 2018/5/1

Y1 - 2018/5/1

N2 - OBJECTIVE: To assess drug susceptibility and characterize Clostridium difficile ribotypes in isolates from two tertiary-care hospitals in Mexico.METHODS: Isolates were evaluated for genotyping, antimicrobial susceptibility testing and detection of mutations associated with drug resistance. PCR ribotyping was performed using a combination of gel-based and capillary electrophoresis-based approaches.RESULTS: MIC50 and MIC90 were ≥128 mg/L for ciprofloxacin, erythromycin, clindamycin, and rifampicin. There was no reduced susceptibility to metronidazole or tetracycline; however, reduced susceptibility to vancomycin (≥4 mg/L) and fidaxomicin (≥2 mg/L) was detected in 50 (40.3%) and 4 (3.2%) isolates, respectively. Furthermore, the rpoB Arg505Lys mutation was more frequently detected in isolates with high minimum inhibitory concentration (MIC) to rifampicin (≥32 mg/L) (OR = 52.5; 95% CI = 5.17-532.6; p < 0.000). Of the 124 C. difficile isolates recovered, 84 (66.7%) were of ribotype 027, 18 (14.5%) of ribotype 001, and the remainder were other ribotypes (353, 255, 220, 208, 176, 106, 076, 020, 019, 017, 014, 012, 003, and 002).CONCLUSION: Ribotypes 027 and 001 were the most frequent C. difficile isolates recovered in this study, and demonstrated higher MICs. Furthermore, we found four isolates with reduced susceptibility to fidaxomicin, raising a concern since this drug is currently unavailable in Mexican Hospitals.

AB - OBJECTIVE: To assess drug susceptibility and characterize Clostridium difficile ribotypes in isolates from two tertiary-care hospitals in Mexico.METHODS: Isolates were evaluated for genotyping, antimicrobial susceptibility testing and detection of mutations associated with drug resistance. PCR ribotyping was performed using a combination of gel-based and capillary electrophoresis-based approaches.RESULTS: MIC50 and MIC90 were ≥128 mg/L for ciprofloxacin, erythromycin, clindamycin, and rifampicin. There was no reduced susceptibility to metronidazole or tetracycline; however, reduced susceptibility to vancomycin (≥4 mg/L) and fidaxomicin (≥2 mg/L) was detected in 50 (40.3%) and 4 (3.2%) isolates, respectively. Furthermore, the rpoB Arg505Lys mutation was more frequently detected in isolates with high minimum inhibitory concentration (MIC) to rifampicin (≥32 mg/L) (OR = 52.5; 95% CI = 5.17-532.6; p < 0.000). Of the 124 C. difficile isolates recovered, 84 (66.7%) were of ribotype 027, 18 (14.5%) of ribotype 001, and the remainder were other ribotypes (353, 255, 220, 208, 176, 106, 076, 020, 019, 017, 014, 012, 003, and 002).CONCLUSION: Ribotypes 027 and 001 were the most frequent C. difficile isolates recovered in this study, and demonstrated higher MICs. Furthermore, we found four isolates with reduced susceptibility to fidaxomicin, raising a concern since this drug is currently unavailable in Mexican Hospitals.

KW - Clostridium difficile

KW - drug resistance

KW - fidaxomicin

KW - ribotype 001

KW - ribotypes

UR - http://www.scopus.com/inward/record.url?scp=85054460749&partnerID=8YFLogxK

U2 - 10.1089/mdr.2017.0323

DO - 10.1089/mdr.2017.0323

M3 - Article

VL - 24

SP - 386

EP - 392

JO - Microbial Drug Resistance

JF - Microbial Drug Resistance

IS - 4

ER -